Literature DB >> 15768052

Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans.

A Gaedigk1, A Bhathena, L Ndjountché, R E Pearce, S M Abdel-Rahman, S W Alander, L DiAnne Bradford, P K Rogan, J Steven Leeder.   

Abstract

Cytochrome P4502D6 (CYP2D6) genotyping reliably predicts poor metabolizer phenotype in Caucasians, but is less accurate in African Americans. To evaluate discordance we have observed in phenotype to genotype correlation studies, select African American subjects were chosen for complete resequencing of the CYP2D6 gene including 4.2 kb of the CYP2D7-2D6 intergenic region. Comparisons were made to a CYP2D6(*)1 reference sequence revealing novel SNPs in the upstream, coding and intervening sequences. These sequence variations, defining four functional alleles (CYP2D6(*)41B, (*)45A and B and (*)46), were characterized for their ability to influence splice site strength, transcription level or catalytic protein activity. Furthermore, their frequency was determined in a population of 251 African Americans. A -692(TGTG) deletion (CYP2D6(*)45B) did not significantly decrease gene expression, nor could any other upstream SNP explain a genotype-discordant case. CYP2D6(*)45 and (*)46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768052      PMCID: PMC1440720          DOI: 10.1038/sj.tpj.6500305

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  40 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6.

Authors:  S Raimundo; J Fischer; M Eichelbaum; E U Griese; M Schwab; U M Zanger
Journal:  Pharmacogenetics       Date:  2000-10

3.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

4.  Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California.

Authors:  Y J Wan; R E Poland; G Han; T Konishi; Y P Zheng; N Berman; K M Lin
Journal:  Pharmacogenetics       Date:  2001-08

5.  Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.

Authors:  E U Griese; S Asante-Poku; D Ofori-Adjei; G Mikus; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1999-12

6.  Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data.

Authors:  A Gaedigk; R R Gotschall; N S Forbes; S D Simon; G L Kearns; J S Leeder
Journal:  Pharmacogenetics       Date:  1999-12

7.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6.

Authors:  U M Zanger; J Fischer; S Raimundo; T Stüven; B O Evert; M Schwab; M Eichelbaum
Journal:  Pharmacogenetics       Date:  2001-10

8.  Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.

Authors:  T Shimada; F Tsumura; H Yamazaki; F P Guengerich; K Inoue
Journal:  Pharmacogenetics       Date:  2001-03

9.  Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene.

Authors:  J Vockley; P K Rogan; B D Anderson; J Willard; R S Seelan; D I Smith; W Liu
Journal:  Am J Hum Genet       Date:  2000-02       Impact factor: 11.025

10.  Information analysis of human splice site mutations.

Authors:  P K Rogan; B M Faux; T D Schneider
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

View more
  22 in total

1.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

2.  Identification of CYP2D6 impaired functional alleles in Mexican Americans.

Authors:  Huai-Rong Luo; Andrea Gaedigk; Vasileios Aloumanis; Yu-Jui Yvonne Wan
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

3.  The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients.

Authors:  Sinem Yalcıntepe; Ozturk Ozdemır; Coskun Sılan; Filiz Ozen; Ahmet Uludag; Ferhan Candan; Fatma Sılan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-03       Impact factor: 2.441

Review 4.  Sequencing the CYP2D6 gene: from variant allele discovery to clinical pharmacogenetic testing.

Authors:  Yao Yang; Mariana R Botton; Erick R Scott; Stuart A Scott
Journal:  Pharmacogenomics       Date:  2017-05-04       Impact factor: 2.533

5.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

6.  Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.

Authors:  Marianne M Yee; Cassandra Josephson; Charles E Hill; Rosiland Harrington; Marta-Inés Castillejo; Ruan Ramjit; Ifeyinwa Osunkwo
Journal:  J Pediatr Hematol Oncol       Date:  2013-10       Impact factor: 1.289

7.  CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification: Resolution of a Complex Genotype and a Discordant Genotype Involving the CYP2D6*59 Allele.

Authors:  Andrea Gaedigk; Amanda K Riffel; J Steven Leeder
Journal:  J Mol Diagn       Date:  2015-09-01       Impact factor: 5.568

Review 8.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity.

Authors:  Danxin Wang; Ming J Poi; Xiaochun Sun; Andrea Gaedigk; J Steven Leeder; Wolfgang Sadee
Journal:  Hum Mol Genet       Date:  2013-08-28       Impact factor: 6.150

10.  Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients.

Authors:  Peggy A Compton; Walter Ling; Matt A Torrington
Journal:  Addict Biol       Date:  2008-05-26       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.